JP2022519796A5 - - Google Patents
Info
- Publication number
- JP2022519796A5 JP2022519796A5 JP2021523466A JP2021523466A JP2022519796A5 JP 2022519796 A5 JP2022519796 A5 JP 2022519796A5 JP 2021523466 A JP2021523466 A JP 2021523466A JP 2021523466 A JP2021523466 A JP 2021523466A JP 2022519796 A5 JP2022519796 A5 JP 2022519796A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- antibody
- amino acid
- acid sequence
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811283440.7 | 2018-10-31 | ||
| CN201811283440.7A CN111110841A (zh) | 2018-10-31 | 2018-10-31 | 含有抗pcsk9抗体的稳定制剂 |
| PCT/CN2019/114233 WO2020088492A1 (zh) | 2018-10-31 | 2019-10-30 | 含有抗pcsk9抗体的稳定制剂 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519796A JP2022519796A (ja) | 2022-03-25 |
| JP2022519796A5 true JP2022519796A5 (cg-RX-API-DMAC7.html) | 2022-10-24 |
| JP7502286B2 JP7502286B2 (ja) | 2024-06-18 |
Family
ID=70464340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523466A Active JP7502286B2 (ja) | 2018-10-31 | 2019-10-30 | 抗ｐｃｓｋ９抗体を含む安定製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210393777A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3878467A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7502286B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210096105A (cg-RX-API-DMAC7.html) |
| CN (3) | CN111110841A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020088492A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116261448A (zh) * | 2020-08-19 | 2023-06-13 | 百奥泰生物制药股份有限公司 | 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂 |
| CN114344460B (zh) * | 2020-10-13 | 2025-09-19 | 信立泰(成都)生物技术有限公司 | 含有抗pcsk9抗体的稳定制剂及其制备方法和用途 |
| JP2025522576A (ja) * | 2022-06-30 | 2025-07-15 | エーディー ファーマシューティカルズ カンパニー，リミティド | 抗ｐｃｓｋ９抗体製剤及びその応用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| EP2501408B1 (en) * | 2009-11-20 | 2020-05-27 | Biocon Limited | Formulations of antibody |
| EP3409289B1 (en) * | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) * | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| MX2018003298A (es) * | 2015-09-22 | 2018-06-20 | Pfizer | Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo. |
| CN106810609A (zh) * | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
-
2018
- 2018-10-31 CN CN201811283440.7A patent/CN111110841A/zh active Pending
-
2019
- 2019-10-30 US US17/290,078 patent/US20210393777A1/en not_active Abandoned
- 2019-10-30 EP EP19878080.1A patent/EP3878467A4/en not_active Withdrawn
- 2019-10-30 KR KR1020217016186A patent/KR20210096105A/ko not_active Withdrawn
- 2019-10-30 CN CN201980071607.XA patent/CN112955180A/zh active Pending
- 2019-10-30 WO PCT/CN2019/114233 patent/WO2020088492A1/zh not_active Ceased
- 2019-10-30 CN CN202511285329.1A patent/CN121130072A/zh active Pending
- 2019-10-30 JP JP2021523466A patent/JP7502286B2/ja active Active